Global Ulcerative Colitis Immunology Drugs Market By Product Type (Adalimumab, Certolizumab Pegol) And By End-Users/Application (Rheumatoid Arthritis, Crohn's Disease(CD)) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-984483
  • April 2021
  • Pharmaceuticals
  • 114 Pages

Report Preview

The Ulcerative Colitis Immunology Drugs Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)

The Ulcerative Colitis Immunology Drugs Market has been valued at US$ xx Mn in the year 2020 and is anticipated to attain US$ xx Mn by the year 2028 along with a CAGR of xx%

Ulcerative Colitis Immunology Drugs Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Ulcerative Colitis Immunology Drugs market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Adalimumab, Certolizumab Pegol, Tofacitinib, Etanercept, Golimumab, Abatacept, Infliximab, Others
Applications Rheumatoid Arthritis, Crohn\'s Disease(CD), Ankylosing Spondylitis(AS), Psoriasis(Ps), Ulcerative Colitis(UC)
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Janssen Biotech, Inc., Bristol-Myers Squibb Company, AbbVie Inc., UCBCares, AMGEN, Celltrion Healthcare, Biogen, Genentech USA, Inc., ROCHE, Pfizer Inc.
 
Ulcerative Colitis Immunology Drugs Market Competitive and Premeditated Analysis
In the Ulcerative Colitis Immunology Drugs report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Ulcerative Colitis Immunology Drugs research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Ulcerative Colitis Immunology Drugs Market Segmentation Analysis:
The Ulcerative Colitis Immunology Drugs market is segmented into various sections such as product types, applications as well as end users and regions. Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

Segmentation based on type includes Adalimumab, Certolizumab Pegol, Tofacitinib, Etanercept, Golimumab, Abatacept, Infliximab, Others   

The application segment includes   Rheumatoid Arthritis, Crohn\'s Disease(CD), Ankylosing Spondylitis(AS), Psoriasis(Ps), Ulcerative Colitis(UC)

Major Key Players for Global Ulcerative Colitis Immunology Drugs Market:
The Ulcerative Colitis Immunology Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Janssen Biotech, Inc., Bristol-Myers Squibb Company, AbbVie Inc., UCBCares, AMGEN, Celltrion Healthcare, Biogen, Genentech USA, Inc., ROCHE, Pfizer Inc.
 
The Ulcerative Colitis Immunology Drugs market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Regional Analysis of the Ulcerative Colitis Immunology Drugs market:
The Ulcerative Colitis Immunology Drugs market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

The Global segmentation of the Ulcerative Colitis Immunology Drugs market:
By Type:
  • Adalimumab
  • Certolizumab Pegol
  • Tofacitinib
  • Etanercept
  • Golimumab
  • Abatacept
  • Infliximab
  • Others

By Application
  • Rheumatoid Arthritis
  • Crohn\'s Disease(CD)
  • Ankylosing Spondylitis(AS)
  • Psoriasis(Ps)
  • Ulcerative Colitis(UC)

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


 
Major Factors Included and highlighted in the Ulcerative Colitis Immunology Drugs report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Ulcerative Colitis Immunology Drugs market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Ulcerative Colitis Immunology Drugs market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Ulcerative Colitis Immunology Drugs market is included in the report.
 
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Ulcerative Colitis Immunology Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Ulcerative Colitis Immunology Drugs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Ulcerative Colitis Immunology Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Ulcerative Colitis Immunology Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Ulcerative Colitis Immunology Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Ulcerative Colitis Immunology Drugs Market Snapshot
          2.1.1. Global Ulcerative Colitis Immunology Drugs Market By Type,2019
               2.1.1.1.Adalimumab
               2.1.1.2.Certolizumab Pegol
               2.1.1.3.Tofacitinib
               2.1.1.4.Etanercept
               2.1.1.5.Golimumab
               2.1.1.6.Abatacept
               2.1.1.7.Infliximab
               2.1.1.8.Others
          2.1.2. Global Ulcerative Colitis Immunology Drugs Market By Application,2019
               2.1.2.1.Rheumatoid Arthritis
               2.1.2.2.Crohn's Disease(CD)
               2.1.2.3.Ankylosing Spondylitis(AS)
               2.1.2.4.Psoriasis(Ps)
               2.1.2.5.Ulcerative Colitis(UC)
          2.1.3. Global Ulcerative Colitis Immunology Drugs Market By End-use,2019
          2.1.4. Global Ulcerative Colitis Immunology Drugs Market By Geography,2019

3. Global Ulcerative Colitis Immunology Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028

5. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028

6. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Ulcerative Colitis Immunology Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Ulcerative Colitis Immunology Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Ulcerative Colitis Immunology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Ulcerative Colitis Immunology Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Ulcerative Colitis Immunology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Ulcerative Colitis Immunology Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Ulcerative Colitis Immunology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Ulcerative Colitis Immunology Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Ulcerative Colitis Immunology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Ulcerative Colitis Immunology Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Ulcerative Colitis Immunology Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Ulcerative Colitis Immunology Drugs Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Ulcerative Colitis Immunology Drugs Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Ulcerative Colitis Immunology Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Ulcerative Colitis Immunology Drugs Providers
        8.4.1 Janssen Biotech, Inc.
                8.1.1 Business Description
                8.1.2 Janssen Biotech, Inc. Geographic Operations
                8.1.3 Janssen Biotech, Inc. Financial Information
                8.1.4 Janssen Biotech, Inc. Product Positions/Portfolio
                8.1.5 Janssen Biotech, Inc. Key Developments
        8.4.2 Bristol-Myers Squibb Company
                8.2.1 Business Description
                8.2.2 Bristol-Myers Squibb Company Geographic Operations
                8.2.3 Bristol-Myers Squibb Company Financial Information
                8.2.4 Bristol-Myers Squibb Company Product Positions/Portfolio
                8.2.5 Bristol-Myers Squibb Company Key Developments
        8.4.3 AbbVie Inc.
                8.3.1 Business Description
                8.3.2 AbbVie Inc. Geographic Operations
                8.3.3 AbbVie Inc. Financial Information
                8.3.4 AbbVie Inc. Product Positions/Portfolio
                8.3.5 AbbVie Inc. Key Developments
        8.4.4 UCBCares
                8.4.1 Business Description
                8.4.2 UCBCares Geographic Operations
                8.4.3 UCBCares Financial Information
                8.4.4 UCBCares Product Positions/Portfolio
                8.4.5 UCBCares Key Developments
        8.4.5 AMGEN
                8.5.1 Business Description
                8.5.2 AMGEN Geographic Operations
                8.5.3 AMGEN Financial Information
                8.5.4 AMGEN Product Positions/Portfolio
                8.5.5 AMGEN Key Developments
        8.4.6 Celltrion Healthcare
                8.6.1 Business Description
                8.6.2 Celltrion Healthcare Geographic Operations
                8.6.3 Celltrion Healthcare Financial Information
                8.6.4 Celltrion Healthcare Product Positions/Portfolio
                8.6.5 Celltrion Healthcare Key Developments
        8.4.7 Biogen
                8.7.1 Business Description
                8.7.2 Biogen Geographic Operations
                8.7.3 Biogen Financial Information
                8.7.4 Biogen Product Positions/Portfolio
                8.7.5 Biogen Key Developments
        8.4.8 Genentech USA, Inc.
                8.8.1 Business Description
                8.8.2 Genentech USA, Inc. Geographic Operations
                8.8.3 Genentech USA, Inc. Financial Information
                8.8.4 Genentech USA, Inc. Product Positions/Portfolio
                8.8.5 Genentech USA, Inc. Key Developments
        8.4.9 ROCHE
                8.9.1 Business Description
                8.9.2 ROCHE Geographic Operations
                8.9.3 ROCHE Financial Information
                8.9.4 ROCHE Product Positions/Portfolio
                8.9.5 ROCHE Key Developments
        8.4.10 Pfizer Inc.
                8.10.1 Business Description
                8.10.2 Pfizer Inc. Geographic Operations
                8.10.3 Pfizer Inc. Financial Information
                8.10.4 Pfizer Inc. Product Positions/Portfolio
                8.10.5 Pfizer Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Ulcerative Colitis Immunology Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Ulcerative Colitis Immunology Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Ulcerative Colitis Immunology Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Ulcerative Colitis Immunology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Ulcerative Colitis Immunology Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Ulcerative Colitis Immunology Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Ulcerative Colitis Immunology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Ulcerative Colitis Immunology Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Ulcerative Colitis Immunology Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Ulcerative Colitis Immunology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Ulcerative Colitis Immunology Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Ulcerative Colitis Immunology Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Ulcerative Colitis Immunology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Ulcerative Colitis Immunology Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Ulcerative Colitis Immunology Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Ulcerative Colitis Immunology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Ulcerative Colitis Immunology Drugs: Market Segmentation 
FIG. 2 Global Ulcerative Colitis Immunology Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Ulcerative Colitis Immunology Drugs Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Ulcerative Colitis Immunology Drugs Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Ulcerative Colitis Immunology Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Ulcerative Colitis Immunology Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Ulcerative Colitis Immunology Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Ulcerative Colitis Immunology Drugs Providers, 2019
FIG. 11 Global Ulcerative Colitis Immunology Drugs Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Ulcerative Colitis Immunology Drugs Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Ulcerative Colitis Immunology Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Ulcerative Colitis Immunology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Ulcerative Colitis Immunology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Ulcerative Colitis Immunology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Ulcerative Colitis Immunology Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Ulcerative Colitis Immunology Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Ulcerative Colitis Immunology Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Ulcerative Colitis Immunology Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Ulcerative Colitis Immunology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Ulcerative Colitis Immunology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Ulcerative Colitis Immunology Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Ulcerative Colitis Immunology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Ulcerative Colitis Immunology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Ulcerative Colitis Immunology Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Ulcerative Colitis Immunology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Ulcerative Colitis Immunology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Ulcerative Colitis Immunology Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Ulcerative Colitis Immunology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Ulcerative Colitis Immunology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Ulcerative Colitis Immunology Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Ulcerative Colitis Immunology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Ulcerative Colitis Immunology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Ulcerative Colitis Immunology Drugs Market Value, By Country, 2018 – 2028
TABLE  Janssen Biotech, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AbbVie Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  UCBCares: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AMGEN: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celltrion Healthcare: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biogen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Genentech USA, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ROCHE: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Ulcerative Colitis Immunology Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Ulcerative Colitis Immunology Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Ulcerative Colitis Immunology Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Ulcerative Colitis Immunology Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Ulcerative Colitis Immunology Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Ulcerative Colitis Immunology Drugs Providers, 2016
FIG.  Global Ulcerative Colitis Immunology Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Adalimumab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Certolizumab Pegol Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Tofacitinib Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Etanercept Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Golimumab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Abatacept Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Infliximab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ulcerative Colitis Immunology Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Rheumatoid Arthritis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Crohn's Disease(CD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ankylosing Spondylitis(AS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Psoriasis(Ps) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ulcerative Colitis(UC) Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Ulcerative Colitis Immunology Drugs Market Value, 2018 – 2028, (US$ Mn)